Search This Blog

Monday, December 23, 2019

Zosano +6% premarket on NDA submission for Qtrypta

Zosano Pharma (NASDAQ:ZSAN) has submitted a 505(b)(2) New Drug Application (“NDA”) for Qtrypta for the acute treatment of migraine.
The company expects to receive notification from the FDA confirming whether the submission was accepted for filing for substantive review in March 2020.
Shares are up 6% premarket.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)